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autopsy examinations; there was a 6% frequency among leukemic patients and a 0.5% frequency among patients with other cancers [21] . A total of 93 cases were found among 3,374 reports of autopsy examinations in a later series from the National Institutes of Health [22] .
More recently, however, there has been a disturbing change in the pattern of aspergillosis. While this infection was almost exclusively seen in leukemic patients in the past, the spectrum of underlying diseases associated with aspergillosis today is very broad [23] . Furthermore, the incidence of this infection among leukemic patients has increased significantly. Aspergillosis is also occurring earlier during initial remission induction therapy [2] . Analysis of the experience at the M. D. Anderson Cancer Center (Houston) over two decades provides an example of the changing pattern of aspergillosis [23] . The presence of newly recognized fungal pathogens, such as Fusarium species, Curvularia species, Trichosporon species, and others, had been thought to represent contamination or harmless colonization when these species were isolated from humans. More recently, the role of these and other newly recognized fungi as serious pathogens in patients with cancer has been clearly established [6] [7] .
Factors Predisposing to Fungal Infections
Several factors predispose patients to invasive fungal infections. Defects of immune cells and ulcerations of the skin, oropharynx, and gastrointestinal tract are all known predisposing factors. Presence of any one of these defects may predispose a patient to infection, although it is not unusual for some patients to suffer from multiple defects simultaneously.
Neutropenia is probably one of the most important factors responsible for the increased frequency of fungal infections [4] . The duration of neutropenia depends primarily on the underlying disease and its treatment. Patients are at greatest risk for serious fungal infections when their neutrophil count falls below 100 cells/mL and when this profound neutropenia persists for >1 week. In addition, the trend exhibited by the neutrophil count is an important determinant of the course of the infection: a rising count during therapy is associated with a more favorable prognosis than a count that continues to decrease or one that remains low. In vitro, neutrophils ingest and kill Candida albicans and hence are recognized as the primary defense against infection caused by this organism [25] [26] [27] [28] . The importance ofneutrophils and macrophages in protecting against aspergillosis has also been documented. In vitro, macrophages prevent germination and kill spores, whereas neutrophils protect against hyphae [29] . Recent work in our laboratory indicates that similar defense mechanisms may be responsible for the control of infection by Fusarium species (unpublished observation from our laboratory). It is also likely that neutrophils may play an important role in protecting against trichosporosis, given the high incidence of neutropenia among patients with this infection, the poor response to antifungal chemotherapy ifneutropenia persists [5] , and the increased mortality and tissue fungal burden among neutropenic animals compared with controls (unpublished observation from our laboratory).
The ulcerations in the oropharynx and along the entire gastrointestinal tract caused by chemotherapeutic agents for treatment of cancer set the stage for colonization and invasion by Candida species. It is well established that the use of broad-spectrum antibacterial agents, particularly those that achieve a high concentration in the gastrointestinal tract and that exhibit good activity against gram-negative anaerobes, results in a substantial increase in the gastrointestinal concentrations of Candida species. This increased concentration, together with ulcerations following cytotoxic chemotherapy, may lead to disseminated candidiasis. Other factors known to predispose patients with cancer to Candida infections include adrenal corticosteroid therapy, abdominal surgery, and concomitant diabetes mellitus. Whether central venous catheterization and the administration of total parenteral nutrition predispose patients to disseminated candidiasis remains controversial, although several reviews implicate these factors in the pathogenesis of disseminated infection.
Adrenal corticosteroid therapy and neutropenia are the two most important predisposing factors for the development of aspergillosis and tend to act in concert, thus increasing the risk of infection [29] [30] [31] .
Candidiasis
Candidiasis remains the most frequently encountered fungal infection in patients with cancer [2, 3, 5, 12-16]. For many years, C. albicans was responsible for the vast majority of these infections. In recent years, other species including Candida tropicalis, Candida parapsilosis, Candida guilliermondii, Candida krusei, and Candida lusitaniae have emerged as important pathogens in patients with cancer [12, [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] . With the introduction of antifungal prophylaxis with the newer triazoles, it is possible that this trend for infection with non-albicans species will be further accentuated and that C. krusei and Torulopsis glabrata will account for an increasing number of cases of disseminated candidiasis. Candida species can cause a variety of infections that can be either localized-such as oral thrush, esophagitis, peritonitis, and superficial urinary and cutaneous infections-or disseminated.
The spectrum of disseminated candidiasis in the neutropenic patient with cancer includes both an acute and a chronic presentation. Acute disseminated candidiasis (ADC) may be sudden in onset and usually evolves over days, with skin lesions, fungemia, and sometimes shock [42] , while the chronic form of the infection-referred to as hepatosplenic candidiasis-extends over several months and is characterized by progressive debilitation [43] . Despite these differences, it is wise to consider these two aspects of disseminated candidiasis as occurring on a continuum. Although it is believed that the chronic infection usually follows an acute episode, the chronic syndrome may also convert to an acute infection when the patient's immune status suffers further deterioration.
Chronic 
Aspergillosis
Aspergillus species are ubiquitous organisms, commonly found in soil, water, organic debris, and decaying vegetation [70] . In worldwide surveys of airborne fungi, Aspergillus spores accounted for 0.1%-22% of total spores collected, ranking Aspergillus species first to 15th in frequency among airborne molds. In the hospital setting, Aspergillus species can be isolated from the air, accumulated dust, and environmental surfaces. Most nosocomial aspergilloses are acquired via airborne transmission.
Colonization of the respiratory tract is followed by invasive disease if predisposing factors are present. Sources of airborne fungi in microepidemics have frequently been associated with construction within the hospital or at adjacent sites [71] [72] [73] [74] . Disturbance of dust above false ceilings represents a significant risk to susceptible patients, and dust-generating activities, such as vacuuming, should be avoided in hospitals that care for patients at high risk for aspergillosis. In one study, fire-proofing material was contaminated with Aspergillus spores, and in two other studies, hospital air ducts were contaminated by bird droppings [75] [76] [77] . In most cases, the air supply of the patient's room has been found to be contaminated [76, 78] . However, contamination of the operating room or the radiology department has been associated with microepidemics of aspergillosis.
Guidelines for hospital construction include the following: (1) sealing off areas of patient care from the construction activity with impermeable plastic barriers, and removing seriously immunocompromised patients from floors adjacent to construction activity (these patients should not be readmitted to renovated areas before these areas have been thoroughly cleaned) and (2) ensuring that the ventilation system near the construction area is working properly and is not circulating contaminated air from construction sites to other hospital areas [79] .
Microepidemics of aspergillosis may be difficult to recognize. Only a few patients (those who are immunocompromised) may develop the infection. The common source may not always be detected, but if one is present, it is usually a defective or contaminated ventilation system [72, 74] . Because air sampling may be inadequate for detecting the source, the filtering system and intake ducts must be examined for contamination. Copper Probably the most important factor predicting the outcome of infection due to Fusarium is the immune status of the host. All patients with an underlying malignancy and disseminated fusarial infection had severe neutropenia at the onset of their infection [7] . Except for three patients reported by Merz et al. [86] , no patient with disseminated multiple-organ infection survived even when adequate doses of amphotericin B were given.
In the above-mentioned report, three of four patients with disseminated fusarial infection responded. Of note, in two of these three patients myelosuppression rapidly resolved and there did not appear to be extensive multiple-organ infection. Because of the paucity of data on the management of invasive fusarial infections, we developed a murine model of systemic fusariosis in CFi male mice made by injection of 1 X 106 conidia of Fusarium solani. The activity of the triazoles-fluconazole, itraconazole, saperconazole, and SCH 39304-at doses of 50 mg/kg twice daily was compared with the activity of amphotericin B at doses of 1 and 2 mg/kg injected ip daily. As expected from the poor activity of amphotericin B against disseminated human fusarial infections, amphotericin B therapy was not associated with prolongation of survival or significant reduction in fungal clearance from the organs in treated compared with control animals, despite administration of escalating doses of the drug. Treatment with the triazoles, particularly SCH 39304 and fluconazole, led to significantly longer survival [87] . However, the triazole doses given were significantly higher than standard doses. The use of combination chemotherapy is currently being investigated in this animal model. Trichosporon beigelii. Not much is known about the pathogenesis and treatment of infection caused by Trichosporon beigelii. The most likely primary source of the infection is the patient's own gastrointestinal and respiratory flora, which have been shown to be sites of fungal colonization in hospitalized patients.
The most important systemic host factors for this infection are similar in many respects to those for disseminated candidiasis. They include granulocytopenia and the administration of adrenal corticosteroids [5] . Hemochromatosis and the presence of a prosthetic cardiac valve are also known predisposing factors for disseminated trichosporosis [5, 88] . It is not surprising that Trichosporon species may have (as do other microbial agents) a siderophore receptor, and iron stores in the host may very well be important in the pathogenesis of trichosporosis. It is interesting to note that most reported cases of T. beigelii infection were in the United States, whereas infections caused by Trichosporon capitatum were more commonly encountered on the European continent.
The clinical presentation of disseminated trichosporosis mimics that of disseminated candidiasis and may be acute or chronic. Acute disseminated trichosporosis may have a sudden onset; be associated with skin lesions, fungemia, pulmonary infiltrates, renal and ocular involvement, and hypotension; and usually evolves over days [5] ; whereas chronic disseminated trichosporosis extends over several months and is characterized by progressive debilitation. Chronic disseminated trichosporosis presents clinically in the same way as does CDC (also known in the literature as hepatosplenic candidiasis).
The diagnosis of disseminated trichosporosis rests on a combination of clinical and laboratory findings. Histopathologically, the infection is characterized by the presence of arthroconidia, blastoconidia, hyphae, and pseudohyphae. 
Therapy for Invasive Mycoses
A major obstacle to the successful management of serious fungal infections is the inability to establish the diagnosis. Thus, empiric therapy with amphotericin B has become standard practice for the management of neutropenic patients with persistent fever that is unresponsive to therapy with antibacterial agents. One study evaluated neutropenic patients who had fever of unknown origin for 1 week after receiving an antibacterial regimen [93] . Patients were randomly assigned to three groups: (1) to continue the same antibacterial regimen, (2) to discontinue all antibacterial therapy, or (3) to receive amphotericin B in addition to the antibacterial regimen. Significantly fewer fungal infections were documented in the group of patients receiving amphotericin B.
Another prospective study randomly assigned patients who remained febrile after 4 days of antibacterial therapy to two groups: (1) to continue the same antibacterial regimen or (2) to receive amphotericin B in addition. The subsequent response rates were 53% and 69%, respectively (P = .09) [94] .
Empirical therapy with amphotericin B is clearly indicated for some patients, but unfortunately, many patients who do not have fungal infection suffer the toxicities of amphotericin B unnecessarily. In addition, amphotericin B-deoxycholate may not be well available to fungi. Despite the presence of high drug concentrations in various tissues of patients with cancer on whom an autopsy was performed and despite the good susceptibility of these fungi in vitro to the drug, in one study patients still died of disseminated fungal infections and were determined to have had extensive mycoses at the time autopsy was performed [95] .
In another study of patients with cancer succumbing to fungal infections, amphotericin B was detected in very small concentrations in kidneys and lungs, which are usual sites of serious mycoses; fungicidal concentrations of the drug were seldom achieved in tissues; and biodiffusion and bioavailability of the drug were poor [96] . In addition, substances in serum and tissue seem to inhibit the fungicidal activity of amphotericin B [97] . In vitro, Candida species can convert to slow anaerobic growth in the presence of amphotericin B and thus not be susceptible to the fungicidal effect of the drug [98] . Since no prospective studies have addressed the role of amphotericin B in the therapy for ADC, one must rely on retrospective analysis of patients treated with this drug. Overall, a 45% response rate has been reported in a cumulative review [99] . However, a recent study indicated that no significant differences in rates of survival could be observed between patients with disseminated candidiasis who received amphotericin B and those who did not [100] . Although the latter was a retrospective study, the serious limitations of the use of amphotericin B, particularly in severely immunocompromised patients, were nonetheless indicated. On the other hand, another retrospective study indicated that use of amphotericin B early in the course of infection decreased the mortality associated with fungal infection and reduced the incidence of disseminated mycoses and the frequency of persistent fungemia [101] .
The apparent lack of activity ofamphotericin B in severely ill patients has been further compounded by the emergence of resistance to this agent in this patient population [ 
Conclusions
We have learned several lessons from our experience and those of others with fungal infections and antifungal chemotherapy. Clearly, amphotericin B is not an "all-around" antifungal agent, given the very high rate of failure among immunosuppressed patients with cancer (nor is it likely that any such "all-around" agent will be available soon). We have also learned that the status of the immune system is the most important predictor of outcome in cases of invasive mycoses and that fungi that were considered simple colonizers or contaminants only a few years ago have now emerged as significant pathogens in this patient population. Only through collaboration between clinicians, pathologists, microbiologists, and pharmacologists can these fungal infections be recognized and treated effectively. It is hoped that the advent of newer antifungal agents and biological response modifiers will result in significant improvement in the prevention and treatment of these life-threatening opportunistic infections.
